We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Immunocore Named One of Fierce 15 Leading Biotechs of 2013


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Immunocore Named One of Fierce 15 Leading Biotechs of 2013"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Immunocore Limited has been named by FierceBiotech as one of 2013’s Fierce 15 biotechs, designating it as one of the most promising private biotechnology companies in the industry. This is Fierce Biotech’s eleventh annual Fierce 15 selection.

“Immunocore offers an interesting early-stage approach to rallying the immune system against cancer,” said FierceBiotech Executive Editor Ryan McBride. “Its T-cell receptor technology has taken many years to invent from scratch, and the hard work has begun to pay dividends with two recent pharma partnership deals.”

The company’s world-leading platform of bi-specific biological drugs, called ImmTACs (Immune mobilizing mTCR Against Cancer), exploit the power of T Cell Receptors (TCRs) to recognize intracellular changes that occur during cancer or viral infection.

This unique recognition ability of TCRs sets them apart from traditional antibody-based therapies that can only recognize changes on the surface of cells, and provides, for the first time, the ability to develop extremely potent targeted therapies for cancers that are poorly served.

A particular feature is that the ImmTACs can be directed to target and destroy only the cancerous cells, avoiding damage to healthy cells.

The most advanced ImmTAC drug, IMCgp100 for the treatment of melanoma, is in Phase I/II clinical trials in the UK and USA.

This summer, Immunocore announced two major partnership agreements with Genentech, a member of Roche Group, and GlaxoSmithKline to discover, develop and commercialize ImmTAC therapies against multiple targets.

James Noble, Chief Executive Officer of Immunocore, commented: “We are delighted to receive this prestigious award from FierceBiotech and be ranked among the top private biotech firms globally. This award recognizes 14 years of work to develop our technology and create a robust and reproducible platform, which has been validated through our two significant partnership deals, enabling our ImmTACs to be deployed as the basis of breakthrough treatments for cancers where there is a large unmet medical need.”

The Fierce 15 celebrates the spirit of being “fierce” - championing innovation and creativity, even in the face of intense competition.

An internationally recognized daily newsletter reaching more than 100,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories.

Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

A complete list of “Fierce 15” companies - the online newsletter’s eleventh annual selection - is available at www.fiercebiotech.com.

Advertisement